Blood substitutes

Claim 3

The method of claim 1 wherein the mutant hemoglobin is a naturally-occurring hemoglobin.

Claim 4

The method of claim 1 wherein the mutant hemoglobin is a non-naturally-occurring hemoglobin.

Claim 5

The method of claim 1 wherein the cell-free mutant hemoglobin has a P 50 of at least about 10% greater than that of cell-free conventional hemoglobin under the same conditions.

Claim 6

The method of claim 1, wherein the mutant hemoglobin contains a mutation which affects the equilibrium between the R state and the T state of the hemoglobin molecule.

Claim 7

The method of claim 1, wherein the mutant hemoglobin contains a mutation of the beta Asn102 (G4) residue.

Claim 8

The method of claim 6, wherein the mutant hemoglobin contains a beta Asn102 (G4)→Thr mutation.

Claim 9

The method of claim 1, wherein the mutant hemoglobin contains a H is 63 Phe mutation.

Claim 11

The method of claim 1, wherein the mutant hemoglobin contains a mutation of a first amino acid residue on a first chain which is within 4 angstroms of a second residue on a second and distinct chain, as determined on a nearest atom-to-nearest atom basis, wherein said first and second residues are a part of the alpha1beta2 or alpha2beta1 interfaces.

Claim 12

The method of claim 10, wherein the mutant hemoglobin contains a mutation of beta residue 45 (CD4).

Claim 13

The method of claim 10, wherein the mutant hemoglobin contains a mutation of beta residue 70 (E14).

Claim 14

The method of claim 1, wherein the mutant hemoglobin contains a mutation of beta 67 Val.

Claim 15

The method of claim 1, wherein the mutant hemoglobin contains a mutation of beta 67 Val→Ile.

Claim 16

The method of claim 4, wherein the mutant hemoglobin is a non-naturally-occurring hemoglobin.

Claim 17

The method of claim 1, wherein the composition further comprises an organic phosphate which stabilizes the T state of hemoglobin.

Claim 18

The method of claim 1, wherein the mutant hemoglobin contains a mutation wherein another amino acid residue is converted to cyrsteine, and wherein said cysteine is cross-linked to another cysteine residue.

Claim 19

A nontoxic pharmaceutical composition comprising a non-naturally occurring mutant hemoglobin in a pharmaceutically acceptable carrier.

Claim 20

A nontoxic pharmaceutical composition comprising a non-naturally occurring mutant hemoglobin in a pharmaceutically acceptable carrier.

Claim 21

A hemoglobin composition comprising cell-free, non-pyridoxylated, biologically functional hemoglobin, said hemoglobin being derived from recombinant non-erythrocyte cells, said composition being absolutely free of erythrocyte-specific membrane constituents other than hemoglobin, wherein said hemoglobin has an affinity for oxygen which is lower than that of the conventional hemoglobin depicted in FIG. 1.

Claim 22

A hemoglobin composition comprising cell-free, non-pyridoxylated, biologically functional hemoglobin, said hemoglobin being derived from recombinant non-erythrocyte cells, said composition being absolutely free of erythrocyte-specific membrane constituents other than hemoglobin, wherein said hemoglobin has an affinity for oxygen which is lower than that of the conventional hemoglobin depicted in FIG. 1.

Claim 23

The hemoglobin composition of claim 19, wherein said hemoglobin is an alpha chain hemoglobin mutant.

Claim 24

The hemoglobin composition of claim 19, wherein the hemoglobin has the structure of a natural low affinity hemoglobin mutant selected from the group consisting of the mutants Hirosaki, Torino, Moabit, Titusville, Raleigh, Connecticut, Moscva, Rothschild, Hazebrouck, Hammersmith, Louisville, Sendagi, Cheverley, Okaloosa, Bologna, Cairo, Chico, Bristol, Seattle, Vancouver, Korle-Bu, Mobile, Rahere, Pyrgos, Roseau-Pointe, Agenogi, Caribbean, Kansas, Beth Israel, Saint Mande, Richmond, Burke, Yoshizuka, Presbyterian, Peterborough, New York, Hope, and Himeji.

Claim 25

The method of claim 2 wherein the mutant hemoglobin has the structure of a natural low affinity hemoglobin mutant selected from the group consisting of mutants Hirosaki, Torino, Moabit, Titusville, Raleigh, Connecticut, Moscva, Rothschild, Hazebrouck, Hammersmith, Louisville, Sendagi, Cheverley, Okaloosa, Bologna, Cairo, Chico, Bristol, Seattle, Vancouver, Korle-Bu, Mobile, Rahere, Pyrgos, Roseau-pointe, Agenogi, Caribbean, Kansas, Beth Israel, Saint Mande, Richmond, Burke, Yoshizuka, Presbyterian, Peterborough, New York, Hope, and Himeji.

Claim 26

The method of claim 3 wherein the mutant hemoglobin is a low affinity hemoglobin mutant selected from the group consisting of mutants having at least one of the alpha-chain mutations 46 phe→thr, 46 phe→ser, 46 phe→ala, 58 his→phe, 58 his→trp, 61 lys→thr, 61 lys→ser, 61 lys→met, 61 lys→asn, 62 val→leu, 62 val→ile, 62 val→phe, 62 val→trp, 65 ala→asp, 94 asp→gln, 94 asp→thr, 94 asp→ser, 94 asp→lys, 94 asp→gly, or 94 a sp→arg; and mutants having at least one of the beta chain mutants 21 asp→ala, 21 asp→ser, 45 phe→ala, 45 phe→thr, 45 phe→val, 63 his→phe, 63 his→trp, 66 lys→ser, 66 lys→asn, 67 val→phe, 67 val→trp, 67 val→ile, 70 ala→glu, 70 ala→ser, 70 ala→thr, 96 leu→phe, 96 leu→his, 96 leu→lys, 98 val→trp, 98 val→phe, 102 asn→asp, 102 asn→glu, 102 asn→arg, 102 asn→his, 102 asn→gly, 108 asn→arg, or 108 asn→glu.

Claim 27

A non-naturally occurring low affinity hemoglobin mutant selected from the group consisting of mutants having at least one of the alpha chain mutations 46 phe→thr, 46 phe→ser, 46 phe→ala, 58 his→phe, 58 his→trp, 61 lys→thr, 61 lys→ser, 61 lys→met, 61 lys→asn, 62 val→leu, 62 val→ile, 62 val→phe, 62 val→trp, 65 ala→asp, 94 asp→gln, 94 asp→thr, 94 asp→ser, 94 asp→lys, 94 asp→gly, or 94 asp→arg; and mutants having at least one of the beta chain mutations 21 asp→ala, 21 asp→ser, 45 phe→ala, 45 phe→thr, 45 phe→val, 63 his→phe, 63 his→trp, 66 lys→ser, 66 lys→asn, 67 val→phe, 67 val→trp, 67 val→ile, 70 ala→glu, 70 ala→ser, 70 ala→thr, 96 leu→phe, 96 leu→his, 96 leu→lys, 98 val→trp, 98 val→phe, 102 asn→asp, 102 asn→glu, 102 asn→arg, 102 asn→his, 102 asn→gly, 108 asn→arg, or 108 asn→glu.

Claim 28

A non-naturally occurring low affinity hemoglobin mutant selected from the group consisting of mutants having at least one of the alpha chain mutations 46 phe→thr, 46 phe→ser, 46 phe→ala, 58 his→phe, 58 his→trp, 61 lys→thr, 61 lys→ser, 61 lys→met, 61 lys→asn, 62 val→leu, 62 val→ile, 62 val→phe, 62 val→trp, 65 ala→asp, 94 asp→gln, 94 asp→thr, 94 asp→ser, 94 asp→lys, 94 asp→gly, or 94 asp→arg; and mutants having at least one of the beta chain mutations 21 asp→ala, 21 asp→ser, 45 phe→ala, 45 phe→thr, 45 phe→val, 63 his→phe, 63 his→trp, 66 lys→ser, 66 lys→asn, 67 val→phe, 67 val→trp, 67 val→ile, 70 ala→glu, 70 ala→ser, 70 ala→thr, 96 leu→phe, 96 leu→his, 96 leu→lys, 98 val→trp, 98 val→phe, 102 asn→asp, 102 asn→glu, 102 asn→arg, 102 asn→his, 102 asn→gly, 108 asn→arg, or 108 asn→glu.

Claim 29

A hemoglobin composition comprising a solution of cell-free, mutant hemoglobin in a pharmaceutically acceptable carrier, said solution having a P 50 under standard physiological conditions of 24-32 torr.

Claim 30

A hemoglobin composition comprising a solution of cell-free, mutant hemoglobin in a pharmaceutically acceptable carrier, said solution having a P 50 under standard physiological conditions of 24-32 torr.

Claim 31

The composition of claim 25, wherein said composition further comprises sodium ions, potassium ions and chloride ions.

Claim 32

The composition of claim 26, wherein said composition further comprises an oncotic agent.

Claim 33

The composition of claim 27, wherein said composition further comprises an antioxidant.